148 related articles for article (PubMed ID: 17976271)
21. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin.
Stern RH; Yang BB; Horton M; Moore S; Abel RB; Olson SC
J Clin Pharmacol; 1997 Sep; 37(9):816-9. PubMed ID: 9549635
[TBL] [Abstract][Full Text] [Related]
22. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
[TBL] [Abstract][Full Text] [Related]
23. Atorvastatin and clopidogrel.
Damkier P
Circulation; 2003 Sep; 108(13):e96; author reply e96. PubMed ID: 14517157
[No Abstract] [Full Text] [Related]
24. Atorvastatin does not alter the anticoagulant activity of warfarin.
Stern R; Abel R; Gibson GL; Besserer J
J Clin Pharmacol; 1997 Nov; 37(11):1062-4. PubMed ID: 9506000
[TBL] [Abstract][Full Text] [Related]
25. [Atorvastatin (Lipitor)].
Carpentier Y; Ducobu J; Sternon J
Rev Med Brux; 1999 Oct; 20(5):427-33. PubMed ID: 10582478
[TBL] [Abstract][Full Text] [Related]
26. Do animal models of vein graft atherosclerosis predict outcomes in man?
Yazdani SK; Otsuka F; Nakano M; Finn AV; Virmani R
Atherosclerosis; 2012 Jul; 223(1):102-5. PubMed ID: 22658552
[No Abstract] [Full Text] [Related]
27. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Ajamieh H; Farrell G; Wong HJ; Yu J; Chu E; Chen J; Teoh N
J Gastroenterol Hepatol; 2012 Aug; 27(8):1353-61. PubMed ID: 22432744
[TBL] [Abstract][Full Text] [Related]
28. Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats.
Dong J; Yu X; Wang L; Sun YB; Chen XJ; Wang GJ
Acta Pharmacol Sin; 2008 Oct; 29(10):1247-52. PubMed ID: 18817631
[TBL] [Abstract][Full Text] [Related]
29. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation.
Morelli A; Chavalmane AK; Filippi S; Fibbi B; Silvestrini E; Sarchielli E; Zhang XH; Vignozzi L; Vannelli GB; Forti G; Maggi M
J Sex Med; 2009 Jan; 6(1):91-106. PubMed ID: 19170840
[TBL] [Abstract][Full Text] [Related]
30. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
Goldstein MR; Mascitelli L; Pezzetta F
Neurology; 2009 Apr; 72(16):1448; author reply 1448-9. PubMed ID: 19380709
[No Abstract] [Full Text] [Related]
31. Antioxidative strategies in cognitive impairment: a novel connection between biliverdin-reductase and statins.
Schneider A; Simons M
J Neurochem; 2012 Jan; 120(1):1-3. PubMed ID: 22017407
[No Abstract] [Full Text] [Related]
32. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
33. Stress on pleiotropic effects of statins.
Mishra PK
Eur J Cardiothorac Surg; 2006 May; 29(5):861-2; author reply 862. PubMed ID: 16520040
[No Abstract] [Full Text] [Related]
34. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Rao N; Dvorchik B; Sussman N; Wang H; Yamamoto K; Mori A; Uchimura T; Chaikin P
J Clin Pharmacol; 2008 Sep; 48(9):1092-8. PubMed ID: 18552277
[TBL] [Abstract][Full Text] [Related]
35. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process.
Kim JS; Kim MS; Park HJ; Jin SJ; Lee S; Hwang SJ
Int J Pharm; 2008 Jul; 359(1-2):211-9. PubMed ID: 18501538
[TBL] [Abstract][Full Text] [Related]
36. [Assessment of hypolipidemic efficacy and safety of various doses of atorvastatin].
Kukharchuk VV; Kaminnĭ AI
Kardiologiia; 2007; 47(10):51-3. PubMed ID: 18260944
[No Abstract] [Full Text] [Related]
37. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers.
Mendoza L; Hajdúch M; Plausinaitis R; Platílová V; Emritte N; Svoboda M
Pharmazie; 2006 Sep; 61(9):805-6. PubMed ID: 17020163
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of atorvastatin in long-term treatment of patients with ischemic heart disease].
Belousov IuB; Leonova MV
Kardiologiia; 2003; 43(4):14-7. PubMed ID: 12968598
[No Abstract] [Full Text] [Related]
40. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1.
Araújo FA; Rocha MA; Mendes JB; Andrade SP
Biomed Pharmacother; 2010 Jan; 64(1):29-34. PubMed ID: 19811885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
